Imatinib mesylate ( ST-571, Gleevec; Novartis Pharma), is the first member of new class of TKIs that acts by inhibiting specific tyrosine kinases like Bcr-Abl fusion oncoprotein in chronic myeloid leukaemia (CML)(8), inhibits the activation of platelet-derived growth factor PDGF() (9),c-Kit and is currently under evaluation in research and clinical trials for several solid tumors (10,11). This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.